Versant Ventures and Qiming Venture Partners USA led a $65m Series A round in Dualitas Therapeutics.

Versant Ventures and Qiming Venture Partners USA, a venture capital firm, led a $65m Series A round in Dualitas Therapeutics, a biotechnology company. "Current therapies for patients with allergic and autoimmune diseases leave important needs unmet, such as faster onset of action and more meaningful clinical benefit. Our lead programs, discovered from the DualScreen bispecific antibody discovery engine, are a new generation of bispecific antibodies aimed at addressing these patient needs," Rich Murray, Dualitas Interim CEO and Board Member.